Xilio Therapeutics, INC. (XLO) — 10-Q Filings

10-Q Filings (6)

• Xilio's Revenue Surges, But Warrant Liabilities Deepen Net Loss — Nov 13, 2025 Risk: high
  Xilio Therapeutics, Inc. reported a significant increase in collaboration and license revenue to $19.066 million for the three months ended September 30, 2025,
• Xilio's Losses Mount Amid R&D Spend, Cash Position Boosted by Offering — Aug 14, 2025 Risk: high
  Xilio Therapeutics, Inc. reported a net loss of $15.844 million for the three months ended June 30, 2025, an increase from $13.925 million in the same period of
• Xilio Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its clinical-stage immuno-oncology programs
• Xilio Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations, inclu
• Xilio Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business act
• Xilio Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Xilio Therapeutics, Inc. (XLO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Xilio Therapeutics, Inc. filed a 10-Q for the period ending March 3

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX